MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Genocea Biosciences Company Profile (NASDAQ:GNCA)

Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.25 (74.04% upside)

Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
Show:
DateFirmActionRatingPrice TargetActions
8/10/2015Needham & Company LLCReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Piper JaffrayReiterated RatingOverweight$18.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2015Piper JaffrayReiterated RatingOverweight$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Needham & Company LLCSet Price TargetBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015FBR & Co.Initiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015Piper JaffrayInitiated CoverageOverweight$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Stifel NicolausReiterated RatingPositive -> Buy$29.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2014Needham & Company LLCInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Stifel NicolausInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Cowen and CompanyInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Citigroup Inc.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/28/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha